Eli Lilly is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.Trading at $852 per share, LLY ...

Pharmaceutical giant Eli Lilly and Co. sued Willow ... tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and Zepbound, which treats obesity.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

VK2735's subcutaneous and oral formulations ... but can the company produce a credible challenger to Eli Lilly's tirzepatide, marketed and sold as Zepbound in obesity and Mounjaro in Type 2 ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

Eli Lilly(NYSE: LLY ... Like its biggest rival on the market, Wegovy, Zepbound is administered via subcutaneous injection once a week. However, some patients don't like to poke needles into ...